ZLSCF (ZYUS Life Sciences) Current Accrued Expense: $4.87 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is ZYUS Life Sciences Current Accrued Expense?

ZYUS Life Sciences ZLSCF Current Accrued Expense is $4.87 Mil as of Mar. 2026. The stock has 7 warning signs investors should review.

ZYUS Life Sciences's Current Accrued Expense for the quarter that ended in Mar. 2026 was $4.87 Mil.

ZYUS Life Sciences's quarterly Current Accrued Expense declined from Sep. 2025 ($6.26 Mil) to Dec. 2025 ($2.05 Mil) but then increased from Dec. 2025 ($2.05 Mil) to Mar. 2026 ($4.87 Mil).

ZYUS Life Sciences's annual Current Accrued Expense declined from Dec. 2023 ($2.43 Mil) to Dec. 2024 ($2.37 Mil) and declined from Dec. 2024 ($2.37 Mil) to Dec. 2025 ($2.05 Mil).

ZYUS Life Sciences Current Accrued Expense Related Terms

ZYUS Life Sciences Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for ZYUS Life Sciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZYUS Life Sciences Current Accrued Expense Chart

ZYUS Life Sciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
0.00 3.33 2.43 2.37 2.05

ZYUS Life Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.26 6.26 6.26 2.05 4.87

ZYUS Life Sciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $4.87 Mil mean?
ZYUS Life Sciences (ZLSCF) has a Current Accrued Expense of $4.87 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on ZYUS Life Sciences and its competitors.
Is ZYUS Life Sciences' Current Accrued Expense too high?
ZYUS Life Sciences' current Current Accrued Expense is $4.87 Mil.
How does ZYUS Life Sciences' Current Accrued Expense compare to RMTI and BTAI?
ZYUS Life Sciences' Current Accrued Expense of $4.87 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on ZYUS Life Sciences and its competitors. ZYUS Life Sciences's current Current Accrued Expense is $4.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, ZYUS Life Sciences (ZLSCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.00 — trading 99.6% below its estimated fair value. The current Current Accrued Expense is $4.87 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For ZYUS Life Sciences (ZLSCF), the current Current Accrued Expense is $4.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZYUS Life Sciences Business Description

Other Exchanges ZYUS:Canada
Address 407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.